Evolving chemotherapeutics


has strong anti-neoplastic properties with a low side effect profile.

Learn more

Novel reformulation

improves outcomes from standard treatment with cornerstone chemotherapeutic drugs, 5-fluorouracil and leucovorin.

Learn more

Investment opportunity

to advance a new generation therapy in the $1 billion oncology injectables market.

Learn more


Deflexifol is our most advanced drug reformulation and has the potential to improve treatment outcomes for patients with metastatic disease. Fivephusion Pty Ltd aims to develop and commercialise proprietary reformulations of widely prescribed anti-metabolic agents targeting solid tissue cancers. Deflexifol is available for licencing or a commercialisation partnership.

Fusing the cornerstone chemotherapeutic drugs 5-fluorouracil and leucovorin, Deflexifol offers the following benefits in treating colo-rectal cancer (CRC) and many other cancers:

• potentially increased efficacy over standard treatments

• simultaneous administration of all therapeutic ingredients

• significantly reduced toxicity

• scalable production

• low cost of manufacturing materials.